CN Patent

CN118307674A — 针对cd73的抗体分子及其用途

Assigned to Surface Oncology Co ltd · Expires 2024-07-09 · 2y expired

What this patent protects

披露了与CD73结合的抗体分子。抗CD73抗体分子可用于治疗、预防和/或诊断癌症。

USPTO Abstract

披露了与CD73结合的抗体分子。抗CD73抗体分子可用于治疗、预防和/或诊断癌症。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN118307674A
Jurisdiction: CN
Classification: —
Expires: 2024-07-09
Drug substance claim: No
Drug product claim: No
Assignee: Surface Oncology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.